GIDYNAMICS CDI FORUS (GID.AX)
-ASX | Prev Close: | 0.60 |
|---|
| Open: | 0.58 |
|---|
| Bid: | 0.57 |
|---|
| Ask: | 0.62 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.58 - 0.60 |
|---|
| 52wk Range: | 0.53 - 0.95 |
|---|
| Volume: | 7,750 |
|---|
| Avg Vol (3m): | 20,699 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical OfficerBusiness Wire(Tue, Apr 30)
- GI Dynamics, Inc. Reports on Progress of the ENDO Trialat Reuters(Thu, Apr 25)
- Change of Directors Interest Noticeat Reuters(Mon, Mar 18)
- EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asiaat Reuters(Mon, Mar 18)
- GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier® Therapy in BrazilBusiness Wire(Wed, Mar 6)
- CMS Medical to Distribute EndoBarrier Therapy in Brazilat Reuters(Tue, Mar 5)
- GI Dynamics, Inc Q4 and Full-Year 2012 Financial Results Call scheduled for 4:30 pm ET todayCCBN(Mon, Mar 4)
- GI Dynamics Announces Commercial Availability of EndoBarrier® Therapy in Israel for the Treatment of Type 2 Diabetes and/or ObesityBusiness Wire(Tue, Feb 26)
- GI Dynamics to Present at the Cowen Healthcare Conferenceat Reuters(Tue, Feb 26)
- Briefing Call and Webcast on Financial Results for 2012at Reuters(Tue, Feb 19)
- Release of Securities from Voluntary Escrowat Reuters(Mon, Feb 18)
- Data Show EndoBarrier® Therapy Demonstrates Glycemic Control in People with Type 2 Diabetes Who are Mildly Obeseat Reuters(Thu, Feb 7)
- U.S. Pivotal Clinical Trial of EndoBarrier Initiatedat Reuters(Tue, Jan 15)
- GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®Business Wire(Tue, Jan 15)
- GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®at Reuters(Tue, Jan 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forGID.AX.
0.91%